Medpace (MEDP) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Medpace (MEDP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·5h ago
More News
Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Danaher Corporation - DHR
Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Danaher Corporation - DHR Rosen Law Firm Announces Investigation of Breaches of Fiduciary...
PR Newswire·17h ago
Corning Rises 62.8% in Three Months: Is the Stock Worth Buying?
GLW's 62.8% stock surge, AI-driven fiber demand, and expanding partnerships signal strong growth momentum and attractive valuation.
Zacks·1d ago
Danaher (DHR) Reports Next Week: Wall Street Expects Earnings Growth
Danaher (DHR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·1d ago
BLCO vs. DHR: Which Stock Should Value Investors Buy Now?
BLCO vs. DHR: Which Stock Is the Better Value Option?
Zacks·13d ago
Can Danaher's Diagnostics Unit Sustain Growth Amid Lower Sales in China?
DHR's Diagnostics unit posts steady Q2 growth, led by Beckman Coulter demand, while China headwinds weigh on results.
Zacks·23d ago
Danaher's Life Sciences Segment Shrinks: What's the Path Forward?
DHR's Life Sciences unit faces revenue declines from weak demand, but new products and biotech advances offer growth potential.
Zacks·29d ago
Hologic's Breast Health Rebound in Motion: How to Play the Stock Now?
HOLX's Breast Health revival, fueled by AI, leadership shifts and product upgrades, is setting up a growth rebound.
Zacks·1mo ago
Danaher's Biotechnology Growth Picks Up: A Sign of More Upside?
DHR's Biotechnology unit grows 6% in Q2, driven by bioprocessing, despite weakness in research equipment demand.
Zacks·1mo ago
Danaher Gains From Business Strength Amid Persisting Headwinds
DHR posts gains in bioprocessing, biotech and diagnostics, while life sciences softness and high debt weigh.